Navigation Links
Stiefel Laboratories Appoints Two New Members to Board of Directors

Private equity investor The Blackstone Group now represented on company's


CORAL GABLES, Fla., Sept. 21 /PRNewswire/ -- Stiefel Laboratories, Inc. today announced the appointment of two new members to the company's board of directors. The appointments include a representative of the private equity firm The Blackstone Group, which recently became a minority-share investor in the company.

Joining the board are Lodewijk J.R. de Vink, a founding member of Blackstone Healthcare Partners LLP (BHP), and Jeffrey S. Thompson, chief operating officer for Stiefel Laboratories.

Charles W. Stiefel is president, chief executive officer and chairman of Stiefel Laboratories.

"I am pleased to welcome Jeff and Lodewijk to the board at this exciting time," Stiefel said. "Their appointments strengthen our board and thus our company. I am confident they will complement the team as our company continues to grow."

Blackstone's $500 million investment in Stiefel Laboratories, a deal which closed August 10, includes the right to designate one member on the company's board of directors.

Lodewijk de Vink has more than 40 years experience in the pharmaceutical and healthcare industries. In addition to working for such companies as Schering-Plough, Credit Suisse First Boston and Warner-Lambert Company as chairman and CEO, de Vink has been a consultant with Blackstone since 2003 and currently sits on several boards including Roche and Alcon.

"An important aspect of our relationship with Blackstone," Stiefel said, "is the ability to leverage its resources and experience. I look forward to working with Lodewijk not only because of his warm persona, but because of the unparalleled experience he brings to the board."

Jeffrey S. Thompson, COO, Stiefel Laboratories, also joins the board. Thompson, who is responsible for operations on a global level including corporate administration, facilities management, supply chain and technical operations, information technology, human resources, legal, quality and corporate compliance, plays a key role in the integration of the company's U.S. and international business. Previously, Thompson served as the President of Glades Pharmaceuticals, a wholly-owned subsidiary of Stiefel.

"Throughout his career at Stiefel Laboratories, Jeff has impressed us with his energy, enthusiasm and vast knowledge of the pharmaceutical industry," Stiefel said. "He was an instrumental part of the recent Connetics acquisition, spending several months living in Palo Alto, Calif. and serving as the on-site integration leader. His management skills have contributed to the organization's growth and success internationally and we know he will be a valuable addition to the board."

The Stiefel Laboratories board of directors also includes: William D. (Bill) Humphries, chief commercial officer; Richard MacKay, president, Stiefel Canada, Inc. and vice chairman of the board; Gabriel McGlynn, senior vice president of EURASIA; Brent Stiefel, executive vice president, global corporate development and product portfolio; Catherine Stiefel, certified public accountant, mergers & acquisitions; and Todd Stiefel, executive vice president, global strategy.

About Stiefel Laboratories, Inc.

Founded in 1847, Stiefel Laboratories (a privately held company) is the world's largest independent pharmaceutical company specializing in dermatology. The company manufactures and markets a variety of prescription and non-prescription dermatological products. Some of the newest and best- known brands include Duac(R) Topical Gel (clindamycin, 1% - benzoyl peroxide, 5%); Evoclin(R) (clindamycin phosphate) Foam, 1%; Luxiq(R) (betamethasone valerate) Foam, 0.12%; MimyX(R); Olux(TM) (clobetasol propionate) Foam, 0.05%; Olux-E(TM) (clobetasol propionate) Foam, 0.05%; Soriatane(R) (acitretin) capsules; Verdeso(TM) (desonide) Foam, 0.05%; Brevoxyl(R) Creamy Wash (benzoyl peroxide, 4% or 8%) packaged in the convenient new Brevoxyl Acne Wash Kit; Oilatum(R); Physiogel(R); Stieprox(R) (ciclopirox olamine); and Sarna(R). Its wholly-owned global network is comprised of more than 30 subsidiaries, manufacturing plants in six countries, research and development facilities on four continents, and products marketed in more than 100 countries around the world.

Stiefel Laboratories supplements its R&D efforts by seeking strategic partnerships and acquisitions around the world. To learn more about Stiefel Laboratories, Inc. visit

SOURCE Stiefel Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. BioRobot MDx standardize your automated protocols in clinical laboratories
2. Distance-Learning Remote Laboratories using LabVIEW
3. States are the best laboratories for healthcare reform
4. Scientific Protein Laboratories Acquired by New York firm
5. Sharon Ethanol appoints operations director
6. Kyron appoints former AMA chairman to board
7. Brady appoints GE efficiency expert as CTO
8. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
9. Johnson Controls appoints Roell to head EOC
10. SecurePipe appoints two senior execs
11. Milwaukees PointOne appoints new president and CEO
Post Your Comments:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
Breaking Biology News(10 mins):